DURHAM, North Carolina, Feb. 20, 2025 (GLOBE NEWSWIRE) — Die Society for Clinical Research Sites (SCRS) und Fortrea (Nasdaq: FTRE), ein führendes globales Auftragsforschungsinstitut (Contract Research Organization, [...] Read more »
La Society for Clinical Research Sites (SCRS) et Fortrea s’associent pour promouvoir la collaboration dans le domaine de la recherche clinique
DURHAM, N.C., 20 févr. 2025 (GLOBE NEWSWIRE) — La Society for Clinical Research Sites (SCRS) et Fortrea (Nasdaq : FTRE), l’une des principales organisations de recherche contractuelle (ORC) à [...] Read more »
Society for Clinical Research Sites (SCRS) e Fortrea Fazem Parceria para Promover a Colaboração na Pesquisa Clínica
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — A Society for Clinical Research Sites (SCRS) e a Fortrea (Nasdaq: FTRE), uma organização líder global de pesquisa por contrato (CRO), tem o prazer de anunciar o [...] Read more »
Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea’s [...] Read more »
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD–19 x FcγRIIb inhibitor of B cell function–
–Topline results from Phase 2 Trial in [...] Read more »
Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda
[Caption] Sabin Vaccine Institute delivered 700 doses of its Marburg vaccine to Rwanda on Oct. 5, 2024.
WASHINGTON, Oct. 05, 2024 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has provided [...] Read more »
Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome
MNV–201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria
In pre–clinical studies, MNV–201 [...] Read more »
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, [...] Read more »
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Sudan Ebolavirus Vaccine
Laboratory at Makerere University Walter Reed Project, where Sabin’s Phase 2 Sudan ebolavirus vaccine clinical trial begins this month.
Read more »
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader Read more »
Fortrea startet KI-Innovationsstudio, um Technologie und menschliche Lösungen zur Verbesserung der Durchführung klinischer Studien zu bündeln
DURHAM, N.C., June 28, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), ein führendes globales Auftragsforschungsinstitut (CRO), gab heute die Einführung seines Innovationsstudios für künstliche Intelligenz (KI) [...] Read more »
Fortrea Lança AI Innovation Studio para Galvanizar Tecnologia e Soluções Humanas para Aprimoramento da Entrega de Ensaios Clínicos
DURHAM, N.C., June 28, 2024 (GLOBE NEWSWIRE) — A Fortrea (Nasdaq: FTRE), uma organização líder global de pesquisa por contrato (CRO), anunciou hoje o lançamento do seu AI Innovation Studio, [...] Read more »
Fortrea lance un studio d’innovation en IA pour galvaniser les solutions technologiques et humaines afin d’améliorer la réalisation des essais cliniques
DURHAM, État de Caroline du Nord, 28 juin 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq : FTRE), un organisme de recherche sous contrat (« ORC ») de premier plan au niveau mondial, a [...] Read more »
Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery
DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the launch of its artificial intelligence (AI) Innovation Studio, signaling a [...] Read more »
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) — The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most [...] Read more »